Your browser doesn't support javascript.
loading
De novo design of potent and selective mimics of IL-2 and IL-15.
Silva, Daniel-Adriano; Yu, Shawn; Ulge, Umut Y; Spangler, Jamie B; Jude, Kevin M; Labão-Almeida, Carlos; Ali, Lestat R; Quijano-Rubio, Alfredo; Ruterbusch, Mikel; Leung, Isabel; Biary, Tamara; Crowley, Stephanie J; Marcos, Enrique; Walkey, Carl D; Weitzner, Brian D; Pardo-Avila, Fátima; Castellanos, Javier; Carter, Lauren; Stewart, Lance; Riddell, Stanley R; Pepper, Marion; Bernardes, Gonçalo J L; Dougan, Michael; Garcia, K Christopher; Baker, David.
Affiliation
  • Silva DA; Institute for Protein Design, University of Washington, Seattle, WA, USA. dadriano@uw.edu.
  • Yu S; Department of Biochemistry, University of Washington, Seattle, WA, USA. dadriano@uw.edu.
  • Ulge UY; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Spangler JB; Department of Bioengineering, University of Washington, Seattle, WA, USA.
  • Jude KM; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Labão-Almeida C; Department of Bioengineering, University of Washington, Seattle, WA, USA.
  • Ali LR; Departments of Biomedical Engineering and Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
  • Quijano-Rubio A; Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Ruterbusch M; Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Leung I; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Biary T; Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Crowley SJ; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Marcos E; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Walkey CD; Department of Bioengineering, University of Washington, Seattle, WA, USA.
  • Weitzner BD; Department of Immunology, University of Washington School of Medicine, Seattle, WA, USA.
  • Pardo-Avila F; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
  • Castellanos J; Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Carter L; Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Stewart L; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Riddell SR; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Pepper M; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Bernardes GJL; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Dougan M; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Garcia KC; Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Baker D; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Nature ; 565(7738): 186-191, 2019 01.
Article in En | MEDLINE | ID: mdl-30626941
ABSTRACT
We describe a de novo computational approach for designing proteins that recapitulate the binding sites of natural cytokines, but are otherwise unrelated in topology or amino acid sequence. We use this strategy to design mimics of the central immune cytokine interleukin-2 (IL-2) that bind to the IL-2 receptor ßγc heterodimer (IL-2Rßγc) but have no binding site for IL-2Rα (also called CD25) or IL-15Rα (also known as CD215). The designs are hyper-stable, bind human and mouse IL-2Rßγc with higher affinity than the natural cytokines, and elicit downstream cell signalling independently of IL-2Rα and IL-15Rα. Crystal structures of the optimized design neoleukin-2/15 (Neo-2/15), both alone and in complex with IL-2Rßγc, are very similar to the designed model. Neo-2/15 has superior therapeutic activity to IL-2 in mouse models of melanoma and colon cancer, with reduced toxicity and undetectable immunogenicity. Our strategy for building hyper-stable de novo mimetics could be applied generally to signalling proteins, enabling the creation of superior therapeutic candidates.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Design / Receptors, Interleukin-2 / Interleukin-2 / Molecular Mimicry / Interleukin-15 Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Nature Year: 2019 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Design / Receptors, Interleukin-2 / Interleukin-2 / Molecular Mimicry / Interleukin-15 Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Nature Year: 2019 Document type: Article Affiliation country: United States